NCT01026597View on ClinicalTrials.gov

Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Healthy
Interventions
DRUG

REGN727

5 IV cohorts (dose 1, 2, 3, 4, and 5)

DRUG

Placebo

5 IV cohorts (dose 1, 2, 3, 4, and 5)

Trial Locations (1)

Unknown

Overland Park

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01026597 - Ascending Dose Study of the Safety and Tolerability of REGN727(SAR236553) in Healthy Volunteers | Biotech Hunter | Biotech Hunter